MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413072 | Name: Cletoquine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cletoquine is a metabolite of a disease-modifying anti-rheumatic and antimalarial drug hydroxychloroquine. It is produced by oxidative N-deethylation of hydroxychloroquine.

Chemical Structure

Cletoquine
Cletoquine
CAS#4298-15-1

Theoretical Analysis

MedKoo Cat#: 413072

Name: Cletoquine

CAS#: 4298-15-1

Chemical Formula: C16H22ClN3O

Exact Mass: 307.1451

Molecular Weight: 307.82

Elemental Analysis: C, 62.43; H, 7.20; Cl, 11.52; N, 13.65; O, 5.20

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 650.00 2 Weeks
50mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1854126-47-8 (deuterated forms d1-d4) 4298-15-1
Synonym
Cletoquine; Cletoquinum; Cletochina; (±)-Desethylhydroxychloroquine; Desethylhydroxychloroquine; Desethyl Hydroxychloroquine; DHCQ
IUPAC/Chemical Name
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)amino)ethanol
InChi Key
XFICNUNWUREFDP-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H22ClN3O/c1-12(3-2-7-18-9-10-21)20-15-6-8-19-16-11-13(17)4-5-14(15)16/h4-6,8,11-12,18,21H,2-3,7,9-10H2,1H3,(H,19,20)
SMILES Code
CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCNCCO
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 307.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kumar M, Topno RK, Dikhit MR, Bhawana, Sahoo GC, Madhukar M, Pandey K, Das P. Molecular docking studies of chloroquine and its derivatives against P23pro-zbd domain of chikungunya virus: Implication in designing of novel therapeutic strategies. J Cell Biochem. 2019 Oct;120(10):18298-18308. doi: 10.1002/jcb.29139. Epub 2019 Jul 16. PMID: 31310373. 2: Steinbronn C, Chhonker YS, Stewart J, Leingang H, Heller KB, Krows ML, Paasche-Orlow M, Bershteyn A, Stankiewicz Karita HC, Agrawal V, Laufer M, Landovitz R, Wener M, Murry DJ, Johnston C, Barnabas RV, Arnold SLM. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations. Clin Transl Sci. 2023 Jul;16(7):1243-1257. doi: 10.1111/cts.13527. Epub 2023 Apr 29. PMID: 37118968; PMCID: PMC10339702. 3: Yeon Lee J, Lee J, Ki Kwok S, Hyeon Ju J, Su Park K, Park SH. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017 Apr;69(4):536-542. doi: 10.1002/acr.22962. Epub 2017 Mar 7. PMID: 27390146. 4: Miller DR, Khalil SK, Nygard GA. Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. DICP. 1991 Dec;25(12):1302-5. doi: 10.1177/106002809102501202. PMID: 1815421. 5: Sok V, Marzan F, Gingrich D, Aweeka F, Huang L. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. PLoS One. 2021 Mar 5;16(3):e0247356. doi: 10.1371/journal.pone.0247356. PMID: 33667247; PMCID: PMC7935301. 6: Noé G, Amoura Z, Combarel D, Lori L, Tissot N, Seycha A, Funck-Brentano C, Zahr N. Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. Ther Drug Monit. 2019 Aug;41(4):476-482. doi: 10.1097/FTD.0000000000000614. PMID: 30807538. 7: McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993;44(5):481-4. doi: 10.1007/BF00315548. PMID: 8359187. 8: Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, Jung SH, Park SW, Chung YJ, Park SH. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016 Jan;68(1):184-90. doi: 10.1002/art.39402. PMID: 26316040. 9: Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D, Furst DE. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002 Jun;46(6):1460-9. doi: 10.1002/art.10307. PMID: 12115175. 10: Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol. 1987 Mar;116(3):379-86. doi: 10.1111/j.1365-2133.1987.tb05852.x. PMID: 3552020. 11: Soichot M, Mégarbane B, Houzé P, Chevillard L, Fonsart J, Baud FJ, Laprévote O, Bourgogne E. Development, validation and clinical application of a LC-MS/MS method for the simultaneous quantification of hydroxychloroquine and its active metabolites in human whole blood. J Pharm Biomed Anal. 2014 Nov;100:131-137. doi: 10.1016/j.jpba.2014.07.009. Epub 2014 Jul 29. PMID: 25165008. 12: Ducharme J, Fieger H, Ducharme MP, Khalil SK, Wainer IW. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol. 1995 Aug;40(2):127-33. doi: 10.1111/j.1365-2125.1995.tb05768.x. PMID: 8562294; PMCID: PMC1365171. 13: Brown RR, Stroshane RM, Benziger DP. High-performance liquid chromatographic assay for hydroxychloroquine and three of its major metabolites, desethylhydroxychloroquine, desethylchloroquine and bidesethylchloroquine, in human plasma. J Chromatogr. 1986 Apr 25;377:454-9. doi: 10.1016/s0378-4347(00)80809-9. PMID: 3711242. 14: Sailler L, Puissant B, Méliani P, Castex JO, Saivin S, Adoue D, Fournie B, Arlet P, Montastruc JL, Lapeyre-Mestre M, Pourrat J, Blancher A. Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients. Ann N Y Acad Sci. 2007 Jun;1108:41-50. doi: 10.1196/annals.1422.005. PMID: 17893969. 15: Iredale J, Wainer IW. Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiral-chiral high-performance liquid chromatography. J Chromatogr. 1992 Jan 17;573(2):253-8. doi: 10.1016/0378-4347(92)80126-b. PMID: 1601957.